Key insights
- Cantor Fitzgerald reiterates an Overweight rating on CVS Health with a $95 price target, citing its defensive qualities and attractive dividend yield. Other firms also maintain positive ratings. However, sentiment suggests the stock might be "priced to perfection." The article also mentions developments in CVS's Medicare Advantage program and FTC settlement, viewed as positive steps.
Investing.com - Cantor Fitzgerald reiterated an Overweight rating on CVS Health (NYSE:CVS) with a price target of $95.00.
The firm noted that CVS Health remains a safe play for investors. The stock currently trades at $78.79, and according to InvestingPro analysis, CVS appears undervalued relative to its Fair Value. The company has maintained dividend payments for 56 consecutive years, currently offering a 3.38% yield—a track record that reinforces its defensive qualities.
Cantor Fitzgerald indicated that sentiment around the stock has some concerns about being "priced to perfection." The stock is trading near its 52-week high of $85.15, having gained 7.2% over the past week. For investors seeking deeper analysis, InvestingPro offers 10 additional ProTips for CVS, plus a comprehensive Pro Research Report covering this healthcare giant.
The firm also commented on the broader managed care sector, stating that Centene is becoming more attractive.
Cantor Fitzgerald said it remains on the sidelines regarding Centene until July Wakely data becomes available.
In other recent news, CVS Health has been the focus of several key developments. The company has made strides in its Medicare Advantage program, with Cantor Fitzgerald reiterating an Overweight rating and a $95 price target, highlighting progress in returning to target margins. Additionally, Omnicare, a subsidiary of CVS Health, has entered into an asset purchase agreement with GenieRx Holdings, setting a floor price for Omnicare’s assets in a court-supervised sale process. Meanwhile, CVS Health’s pharmacy benefit manager, Caremark, and group purchasing organization, Zinc, have moved to withdraw Federal Trade Commission complaints following a proposed consent agreement, as noted by UBS, which reiterated a Buy rating with a $97 price target.
Furthermore, Leerink Partners continues to hold an Outperform rating with a $98 price target on CVS Health stock, viewing the FTC settlement as a positive step that reduces uncertainty in the pharmacy benefit manager business. In broader healthcare industry news, Wells Fargo analysts observed a 2% quarterly decline in U.S. Medicaid enrollment, with California experiencing a notable 3% drop. These developments collectively reflect ongoing changes and strategic moves within CVS Health and the healthcare sector at large.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.